Aclidinium/formoterol demonstrates consistent, statistically significant lung function improvement in the second pivotal efficacy trial. Positive outcomes also were seen in TDI (breathlessness) and SGRQ (quality of life) in this study. Regulatory filings in the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) are planned in Q4 2013. Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc... via Health News from Medical News Today Read More Here..
No comments:
Post a Comment